|View printer-friendly version|
|Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock|
The Company intends to use the net proceeds of this offering for general corporate purposes, including working capital, research and development activities, capital expenditures and potential strategic transactions.
The underwriter intends to offer the shares from time to time for sale in one or more transactions on The NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.
BofA Merrill Lynch is acting as the sole underwriter of this offering.
The shares are being issued pursuant to an effective shelf registration
statement. Before you invest, you should read the prospectus included in
that registration statement and the documents incorporated by reference
in that registration statement as well as the prospectus supplement
related to the offering. You may obtain these documents free of charge
by visiting EDGAR on the
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s common stock, nor shall there be any sale of the common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state. This offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective shelf registration statement.
Except for the historical information contained herein, the matters set
forth in this press release, including statements with respect to the
anticipated closing date of the offering and the intended use of net
proceeds from the offering, are all forward-looking statements within
the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially, including those related to the satisfaction of the
conditions to closing of the offering, risks relating to our dependence
upon our revenues from JAKAFI, cash requirements arising from the
development of new products by us and our current and potential
collaborators, the risk of significant delays or costs in obtaining
regulatory approvals, risks relating to our collaborators’ ability to
develop and commercialize drug candidates, and cash requirements arising
from our business development activities, the fact that